| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/07/2009 | US7514407 Racemic mixture of proteins |
| 04/07/2009 | US7514406 For treatment of cancers through activation of silenced tumor suppressor genes, promotion of apoptosis in cancerous cells, and inhibition of transcriptional repressor activity in oncogenes; drug screening |
| 04/07/2009 | US7514405 Method involves administering a therapeutically effective amount of Serp-1, its analogs, and biologically active fragments thereof in combination with an anti-rejection agent, such as cyclosporin, and a pharmaceutically acceptable |
| 04/07/2009 | US7514404 PNA-neamine conjugates and methods for producing and using the same |
| 04/07/2009 | US7514403 Process for the stabilization of proteins in an aqueous solution comprising cysteine in a concentration between 150 and 220mM |
| 04/07/2009 | US7514401 Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease |
| 04/07/2009 | US7514399 Use in tissue bonding and protein cross-linking and use in tissue and arterial repair, preservation of expanded internal luminal diameters, and local delivery of drugs, skin care materials, sunscreens, and cosmetics |
| 04/07/2009 | US7514398 Growth factor complex |
| 04/07/2009 | US7514397 Administering homologs of peptides corresponding to amino acid residues 638 to 673, and to amino acid residues 558 to 595, of the human immunodeficiency virus-1LAI transmembrane protein glycoprotein 41; inhibiting membrane fusion |
| 04/07/2009 | US7514261 Platelet-derived growth factor protection of cardiac myocardium |
| 04/07/2009 | US7514254 having hydrolase enzyme activity, used for hydrolsis of an alpha-galactosyl saccharide contained in foodstuff such as soy bean products, thus reducing the capability of the foodstuff to cause flatulence during digestion |
| 04/07/2009 | US7514243 Process for producing dipeptides |
| 04/07/2009 | US7514240 a crystal complex of an epidermal growth factor (EGF) and an epidermal growth factor receptor (EGFR), used for screening and for designing the substance that regulate EGFR activity |
| 04/07/2009 | US7514239 Nucleotide sequences coding polypeptide for use in the treatment of preferential glandular disorders |
| 04/07/2009 | US7514238 Growth factor homolog zvegf4 |
| 04/07/2009 | US7514233 which promote strand transfer activity of viral integrase, such as HIV integrase; screening molecules for antiviral activity comprising exposing the molecules to epithelial growth factors, fragments or nucleotides codes and determining the ability to modulate the interaction with retroviral integrases |
| 04/07/2009 | US7514224 Arrays of PDZ domain polypeptides |
| 04/07/2009 | US7514222 polypeptides or proteins consisting of a four helix bundle formed of two dimerized helix-loop-helix motifs |
| 04/07/2009 | US7514221 Diagnostic assay and method of treatment involving macrophage inhibitory cytokine-1 (MIC-1) |
| 04/07/2009 | US7514207 Administering compound (antibodies, ATP analogs) that inhibits p-21 activated kinase (PAK) activity and/or merlin phosphorylation; drug screening; neurofibromatosis |
| 04/07/2009 | US7514098 Use of targeted cross-linked nanoparticles for in vivo gene delivery |
| 04/07/2009 | US7514095 Three-dimensional chitosan matrix or drug release; tissue engineering ; water in oil emulsion containing active materials; extrusion; coagulation |
| 04/07/2009 | US7514090 Monocyte locomotion inhibitory factor |
| 04/07/2009 | US7514089 Mutant Salmonella species with genetically engineered MSBB gene, expresses altered lipid, has reduced inductino of tumor necrosis factor and increased sensitivity to chelating agents; as antitumor agent |
| 04/07/2009 | US7514087 Administering primer and boosting composition comprising source of one or more CD8+ T cell epitopes of melanoma from a source of non-replicating or replication-deficient recombinant poxvirus vector in the human |
| 04/07/2009 | US7514084 isolated nonapeptide that bind to an human leukocyte antigen (HLA-A 0201) restricted T cell receptors with high affinity and induce a high cytotoxic T lymphocyte response, used for treating or preventing tumors and cancers |
| 04/07/2009 | US7514083 Protein allergens of the species cynodon dactylon |
| 04/07/2009 | US7514082 Virus suppressing factor (VSF) for use in treatment and prevention of viral infection in animal and humans |
| 04/07/2009 | US7514081 administering an isolated antibody or an antigen-binding fragment that binds a novel member of the tumor necrosis factor (TNF) family of cytokines, to inhibit TNF- alpha induction |
| 04/07/2009 | US7514077 administering an antibody that binds Interleukins, to neurons, for the treatment of inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues; antiinflammatory agents; analgesics |
| 04/07/2009 | US7514076 administering a D-amino acid oxidase which is chemically conjugated with a polymer, for accumulation in the tumor tissue, then administering D-amino acid which is a substrate for the D-amino acid oxidase, which releases reactive oxygen species; improved tumor selective cytotoxic activity results |
| 04/07/2009 | US7514073 Reduced vasopermeability activity and similar binding affinity for an IL-2 receptor compared to its wildtype form; immunostimulants; immuotherapy; anticarcinogenic agents; renal cell cancer, melanoma; chemotherapy and/or radiation therapy; viricides; human immunodeficiency virus; autoimmune disorders |
| 04/07/2009 | US7514072 Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia |
| 04/07/2009 | CA2420058C Cyclic peptides having melanocortin-4 receptor agonist activity |
| 04/07/2009 | CA2413190C Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| 04/07/2009 | CA2410065C Micellar pharmaceutical compositions for buccal and pulmonary application |
| 04/07/2009 | CA2341355C Procedure for the chromatographic purification of insulins |
| 04/07/2009 | CA2320072C Erythropoietin liposomal dispersion |
| 04/07/2009 | CA2311643C Compositions and methods for inducing gene expression |
| 04/07/2009 | CA2306447C Purification of molecules |
| 04/07/2009 | CA2269060C Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system |
| 04/07/2009 | CA2237157C Cyclopeptolide inhibitors of adhesion molecules |
| 04/07/2009 | CA2217737C Thf-containing sulfonamide inhibitors of aspartyl protease |
| 04/07/2009 | CA2210871C Human dnase i variants |
| 04/07/2009 | CA2205914C Use of the hepatocyte growth factor to induce proliferation and differentiation of hemopoietic cells |
| 04/07/2009 | CA2176716C Preparation of biodegradable microparticles containing a biologically active agent |
| 04/07/2009 | CA2175332C Haemophilus transferrin receptor genes |
| 04/07/2009 | CA2168570C Use of growth hormone for increasement of concentration of gh, igf-i and igfbp-3 in cerebrospinal fluid |
| 04/07/2009 | CA2151883C Synthetic tropoelastin |
| 04/07/2009 | CA2117492C Bystander suppression of autoimmune diseases |
| 04/07/2009 | CA2102115C In vitro methods for determining in vivo thrombotic events |
| 04/07/2009 | CA2080700C Enzymatic disinsertion of vitreous body |
| 04/02/2009 | WO2009042962A2 Antidotes for factor xa inhibitors and methods of using the same |
| 04/02/2009 | WO2009042906A1 Compositions and methods for camkii inhibitors and uses thereof |
| 04/02/2009 | WO2009042895A2 Reagents for inducing an immune response |
| 04/02/2009 | WO2009042892A1 Cyclic undecapeptides and derivatives as multiple sclerosis therapies |
| 04/02/2009 | WO2009042742A1 Dlx1 cancer markers |
| 04/02/2009 | WO2009042677A2 Stat3 inhibiting compositions and methods |
| 04/02/2009 | WO2009042668A2 Urea-containing peptides as inhibitors of viral replication |
| 04/02/2009 | WO2009042565A2 Inhibitors of eppin/semenogelin binding as male contraceptives |
| 04/02/2009 | WO2009042514A1 Flowable wound matrix and its preparation and use |
| 04/02/2009 | WO2009042294A2 Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof |
| 04/02/2009 | WO2009042215A2 Inhibition of dendritic cell-driven regulatory t cell activation and potentiation of tumor antigen-specific t cell responses by interleukin-15 and map kinase inhibitor |
| 04/02/2009 | WO2009042187A1 Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin |
| 04/02/2009 | WO2009042162A2 Compositions and methods for inhibiting interleukin pathways |
| 04/02/2009 | WO2009041902A1 Prion protein derived cell penetrating peptides and their uses |
| 04/02/2009 | WO2009041841A1 Peptide-platinum complexes, method for preparation and use the same |
| 04/02/2009 | WO2009041037A1 Drug for suppressing pathogen occurring in vivo |
| 04/02/2009 | WO2009041026A1 Cxcl10 production inhibitor |
| 04/02/2009 | WO2009040849A1 Use of amino acid l-kynurenine and derivatives thereof for the treatment of chronic inflammatory pathologies |
| 04/02/2009 | WO2009040814A1 Use of copolymer 1 for treatment of muscular dystrophy |
| 04/02/2009 | WO2009040778A2 Pharmaceutical compositions containing the enzyme cyprosin, an aspartic peptidase from cynara cardunculus and its inclusion in antitumour formulations |
| 04/02/2009 | WO2009040726A2 Rhamnose antagonists and use thereof |
| 04/02/2009 | WO2009040543A2 Bioactive peptide |
| 04/02/2009 | WO2009040418A1 Use of soluble ceacam8 for diagnosing, treating or monitoring diseases, and a method for screening compounds that prevent apoptosis |
| 04/02/2009 | WO2009040338A1 Designed armadillo repeat proteins |
| 04/02/2009 | WO2009040310A1 Prevention of allergy at weaning |
| 04/02/2009 | WO2009040089A2 Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeutic agents |
| 04/02/2009 | WO2009040088A1 Use of peptide kvlpvpq as a therapeutic agent |
| 04/02/2009 | WO2009040087A2 Therapeutic use of peptide yglf and combination with kvlpvpq |
| 04/02/2009 | WO2009040086A2 Use of salusin-alpha as a therapeutic agent |
| 04/02/2009 | WO2009040085A2 Use of exendin-4 and optionally salusin-alpha as therapeutic agent(s) |
| 04/02/2009 | WO2009040084A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040083A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040073A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040072A2 Use of angiotensin i as a therapeutic agent in the treatment of eg aids or tuberculosis |
| 04/02/2009 | WO2009040071A2 Use of cyclo-rgdfv and optionally angiotensin i as therapeutic agents in the treatment of eg aids or tuberculosis |
| 04/02/2009 | WO2009040070A2 Use of helodermin as a therapeutic agent |
| 04/02/2009 | WO2009040069A2 Use of bq-610 alone or in combination with helodermin as a therapeutic agent |
| 04/02/2009 | WO2009040068A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040067A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040051A2 Use of the peptide rfmwmk alone or in combination with the peptide ymdgtmsqv as a therapeutic agent |
| 04/02/2009 | WO2009040050A2 Use of calcitonin as anti-angiogenic agent |
| 04/02/2009 | WO2009040049A2 Use of acetyl- (ala10, 11)-rantes (1-14) and/or calcitonin as anti-angiogenic agents |
| 04/02/2009 | WO2009040048A2 Use of the c-reactive peptide as a therapeutic agent |
| 04/02/2009 | WO2009040047A2 Therapeutic uses of ghrelin and combinations with stresscopin |
| 04/02/2009 | WO2009040046A2 Use of stresscopin-related peptide as a therapeutic agent |
| 04/02/2009 | WO2009040045A2 Use of tyr-w-mif-1 and urocortin 2 as therapeutic agents |
| 04/02/2009 | WO2009040036A2 Use of a galanin peptide as a therapeutic agent |
| 04/02/2009 | WO2009040035A2 Use of a peptide as a therapeutic agent |